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Background/aim: To examine the effects of hormone replacement therapy (HRT) on mean platelet volume (MPV), lipid profile, and
C-reactive protein (CRP) levels in postmenopausal women who have a high risk and incidence of cardiovascular disease.
Materials and methods: This study was performed retrospectively. Twenty-seven healthy postmenopausal women received 1 mg
estradiol and 2 mg drospirenone orally for 6 months. Twenty-eight healthy postmenopausal women not taking any HRT were admitted
to the study as the control population.
Results: Time effect (independent from group effect) was statistically significant for the MPV variable (P = 0.025), but there was no
significant change in MPV levels and other cardiovascular disease risk markers in women receiving HRT compared to women in the
control group.
Conclusion: Younger postmenopausal women taking HRT and women who initiated hormone therapy close to menopause are not at
increased risk of cardiovascular disease.
Key words: Mean platelet volume, menopause, cardiovascular risk, hormone replacement therapy, lipid profile

1. Introduction
Cardiovascular disease (CVD) is the most common
cause of female death worldwide. While CVD is rare in
premenopausal women, its incidence markedly increases
after menopause. This has been partly attributed to the
decline in circulating levels of estrogen (1). Observational
studies have also shown that hormone replacement
therapy (HRT) reduces the risk of CVD in postmenopausal
women. However, large randomized, controlled trials
have not recommended HRT for CVD treatment during
menopause (2). Nevertheless, there is emerging evidence
that initiation of HRT in close proximity to menopause
may reduce the risk of CVD (3). Overall, there are
conflicting reports, and it is important to clarify whether
HRT prevents or promotes CVD.
Platelets are important for the integrity of normal
homeostasis, and mean platelet volume (MPV), an
accurate measure of platelet size, is an indicator of
platelet function. Large platelets with high MPV values
* Correspondence: ikbal_cekmen@yahoo.com
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are metabolically and enzymatically more reactive than
small platelets and produce more prothrombotic factor
thromboxane A2, increasing the propensity for thrombosis
(4). A high MPV level is a new and independent risk factor
for atherothrombosis and CVD. It has been shown to be
high in acute myocardial infarction, cerebral ischaemia,
and transient ischaemic attacks (5). Moreover, measuring
MPV is a cost-effective and simple procedure.
So far there has been insufficient knowledge about why
young or premenopausal women are safe from CVD, and
why postmenopausal women do not benefit from HRT.
The aim of the present study is to investigate the effect
of low-dose combined oral hormone replacement therapy
on MPV, lipid profile, and C-reactive protein (CRP) levels
in postmenopausal women.
2. Materials and methods
This study was performed retrospectively between
January 2007 and August 2009 at the Medical School of
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Turgut Özal University, Department of Obstetrics and
Gynecology, Ankara, Turkey. Fifty-five healthy, nonobese
postmenopausal women between the ages of 43 and 52,
without any known cardiovascular risk factors, were
included in this study. Patients were excluded from the
study if they had cardiovascular disease, thromboembolic
disease, hypertension, thyroid disease, diabetes mellitus,
acute or chronic inflammatory or infective diseases, anemia,
or alcohol abuse. All subjects were nonsmokers and had
not taken any drugs that affect platelet aggregation. This
information was obtained from the patient care computer
system.
Twenty-seven healthy postmenopausal women
receiving 1 mg estradiol and 2 mg drospirenone (Angeliq
tablet; Bayer Ilaç, İstanbul) for 6 months were placed in the
hormone treatment group. The indications for hormone
replacement were vasomotor symptoms and dyspareunia
caused by vaginal atrophy. Twenty-eight healthy
postmenopausal women not taking any hormone treatment
were admitted to the study as the control population. All
participants had been amenorrheic for 1–3 years or had
serum follicle-stimulating hormone concentration of >25
IU/L. No women had received HRT for at least 3 months
before the study. All subjects were evaluated for the effect of
HRT use for 6 months before and after the study.
Venous blood samples were obtained from the
participants through routine full blood count tests.
Samples were collected in Becton Dickinson Vacutainer
tubes (Becton Dickinson, Rutherford, NJ, USA) containing
tripotassium EDTA. Complete blood count (CBC) analyses
were performed in a Beckmann Coulter analyzer model LH
within 1 h. MPV analyses were performed as part of each
CBC. The MPV reference range in our clinic is 7.8–11.1 fL.
The other parameters measured in fasting blood samples
were glucose, total cholesterol, high-density lipoprotein
(HDL), low-density lipoprotein (LDL), triglyceride, and
CRP.

Continuous variables were inspected for normality
of statistical distribution both graphically and by
Shapiro–Wilk test. Data are reported as mean ± standard
deviation (SD) or median with interquartile range (IQR),
as appropriate. Considering that some clinical variables
are influenced by subject age and menopausal age, HRT
and control groups were standardized with respect to
these 2 covariates. The Mann–Whitney U test was used
to perform the statistical analysis of the variables without
normal distribution. To evaluate group, time, and group
× time interaction effects on clinical variables, 2-way
repeated ANOVA was used with Bonferroni adjustment.
Type-I error rate was taken as α = 0.05. Statistical analysis
was performed using the SPSS 20 (SPSS Inc., Chicago, IL,
USA).
3. Results
There were no differences in age, gravida, parity,
menopausal age, menopausal time, and BMI values
between the analyzed groups. Table 1 shows the clinical
characteristics of the subjects in all groups. Group, time,
and group × time interaction effects were analyzed for
clinical variables. In the HRT group, while the MPV level
was 7.92 ± 0.68 fL at baseline, after 6 months it increased
to 8.04 ± 0.64 fL. In the control group, while the MPV level
was 8.22 ± 0.90 fL at baseline, after 6 months it decreased
to 8.16 ± 0.73 fL. Time effect (independent from group
effect) was statistically significant for the MPV variable (P
= 0.025). Group and group × time interaction effect were
not statistically significant for the MPV variable (P = 0.273
and P = 0.152, respectively) (Table 3).
The group × time interaction effect was statistically
significant for hemoglobin (Hb) and hematocrit (Htc)
values (P = 0.002 and P = 0.037, respectively). The
difference between baseline and 6-month Hb values for the
control group was statistically significant (P = 0.004). The
difference between baseline and 6-month Htc values for

Table 1. The demographic properties of the study and control groups.
HRT (n = 27)
Median (IQR)

Control (n = 28)
Median (IQR)

P

49 (5)

50

0.94

Gravidity

3 (3)

4 (1.5)

0.74

Parity

2 (4)

2 (1)

0.34

Age (years)

Menopause age (years)

47 (6)

48 (4.5)

0.79

Menopause time (years)

1 (2)

2 (1.5)

0.53

BMI-0 (kg/m2)

24.14 (3.91)

26.56 (30.44)

0.08

BMI-6 (kg/m2)

24.35 (4.04)

26.56 (3.74)

0.68

HRT: hormone replacement therapy, BMI-0: pretreatment body mass index,
BMI-6: body mass index after 6 months, IQR: interquartile ranges.
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Table 2. Baseline and 6-month data for subjects.
HRT

Control

Mean ± SD
Hb (g/dL)
Htc (%)
Plt (×103/µL)
MPV (fL)

n

Mean ± SD

n

Baseline

13.78 ± 0.74

27

13.99 ± 0.76

28

6-month

13.94 ± 0.77

27

13.70 ± 0.80

28

Baseline

40.74 ± 2.18

27

41.35 ± 2.61

28

6-month

41.02 ± 2.18

27

40.46 ± 2.13

28

Baseline

287.15 ± 63.31

27

288.36 ± 66.57

28

6-month

286.00 ± 63.25

27

275.18 ± 72.74

28

Baseline

7.92 ± 0.68

27

8.22 ± 0.90

28

6-month

8.04 ± 0.64

27

8.16 ± 0.73

28

PDW (%)

Baseline

16.05 ± 0.41

27

16.28 ± 0.72

28

6-month

16.12 ± 0.44

27

16.18 ± 0.61

28

FG (mg/dL)

Baseline

85.86 ± 8.81

11

89.60 ± 7.17

21

6-month

89.15 ± 6.04

11

89.90 ± 7.32

21

TC (mg/dL)

Baseline

211.15 ± 338.96

11

218.34 ± 36.56

21

6-month

213.20 ± 29.42

11

212.18 ± 31.27

21

LDL (mg/dL)

Baseline

115.09 ± 32.94

11

128.99 ± 31.60

21

6-month

124.64 ± 29.88

11

124.06 ± 35.48

21

HDL (mg/dL)

Baseline

62.33 ± 15.86

11

68.73 ± 19.89

21

6-month

58.67 ± 16.14

11

66.73 ± 19.91

21

TG (mg/dL)

Baseline

112.72 ± 44.94

11

103.42 ± 59.98

21

6-month

130.17 ± 50.12

11

105.69 ± 58.10

21

CRP (mg/L)

Baseline

3.19 ± 3.26

11

3.58 ± 2.54

21

6-month

2.01 ± 1.61

11

2.81 ± 3.37

21

HRT: hormone replacement therapy, Hb: hemoglobin, Htc: hematocrit, Plt: platelet, MPV:
mean platelet volume, PDW: platelet distribution width, FG: fasting glucose, TC: total
cholesterol, LDL: low-density lipoprotein, HDL: high-density lipoprotein, TG: triglyceride,
CRP: C-reactive protein.

the control group was statistically significant (P = 0.024)
(Table 3). Group, time, and group × time interaction
effects were not statistically significant for other clinical
variables. Table 2 shows the baseline and 6-month data for
the subjects.
4. Discussion
In this study, we found a statistically significant increase in
MPV levels from baseline to 6 months. However, there was
no significant difference in MPV levels and other CVD
risk markers between women receiving oral combined
continuous 1 mg estradiol plus 2 mg drospirenone and the
control group.
Postmenopausal women have a high risk and incidence
of CVD, which is attributed to a decline in estrogen
levels. Despite the potential beneficial effects of estrogen
for cardioprotection, including an improvement in lipid
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profiles, endothelial function (6,7), and insulin sensitivity,
it also has adverse effects, such as an increase in serum
triglyceride levels, and effects on vascular inflammatory
markers such as CRP and prothrombotic marker (8).
Nowadays, MPV is thought to play a significant role
in coronary artery disease, diabetes, atherosclerosis,
hypertension, and other vascular insufficiency states (4).
Platelets play an important role in the integrity of normal
homeostasis. Large platelets contain denser granules and
are hemostatically more reactive; therefore, they are more
thrombogenic. MPV, an accurate measure of platelet size,
reflects the activity of platelets (4). Moreover, increased
MPV is now emerging as an independent risk factor for
CVD (5).
Several scientific reports have shown sex-related
differences in platelet count and MPV, which seem to reflect
hormonal profiles. In 1994 Tarantino et al. discovered the
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Table 3. Two-way repeated analysis of variance test results for each clinical parameter.
Effect
HRT
Hb

Group × time

Group × time

Group
MPV Time
Group × time

df

P

11.049

1

0.002

4.572

1

0.037

1.229

1

0.273

5.318

1

0.025

2.114

1

0.152

Control

Baseline

6-month

Baseline

6-month

13.8 ± 0.14

13.94 ± 0.15

13.99 ± 0.14*

13.70 ± 0.15

HRT
Htc

F

Control

Baseline

6-month

Baseline

40.74 ± 0.46

41.01 ± 0.42

41.35 ± 0.46† 40.46 ± 0.41†

HRT

Control

7.98 ± 0.14

8.19 ± 0.14

Baseline

6-month

8.07 ± 0.11

8.1 ± 0.09

HRT

6-month

Control

Baseline

6-month

Baseline

6-month

7.92 ± 0.15

8.04 ± 0.13

8.22 ± 0.15

8.16 ± 0.13

*Difference between baseline and 6-month HB values for control group is statistically significant (P = 0.004)
†Difference between baseline and 6-month HCT values for control group is statistically significant (P = 0.024)

presence of functional estrogen receptors in megakaryocytes
and blood platelets in vitro (9). Butkiewicz et al. (10) showed
higher platelet count and lower MPV levels in women due
to menstrual blood loss. While Bain suggested a similar
correlation (11), other research found no correlation and
no statistically significant differences in MPV between
sexes (12). In another study, platelet count was lower in
postmenopausal women compared to young menstruating
women. However, MPV values were similar in both groups
(13). When evaluating the effect of hormone treatment,
Ranganath et al. (6) showed an increase in platelet count (not
significant) and platelet volume (MPV) (P < 0.05) after 6
weeks of hormone therapy (conjugated equine estrogen 0.625
mg daily combined with L-norgestrel 75 mg daily, from days
17 to 28 of a 28-day cycle). Teede et al. (7) noted no difference
in MPV within 6 months of 2 mg estradiol plus 1 mg of
norethisterone exposure; yet, they noted a trend towards
increased platelet aggregation in the HRT group. In other
studies, the effects of HRT on platelet function were evaluated
by measuring platelet aggregation, fatty acid composition of
platelet membranes, and urinary thromboxane B2 excretion
(14,15). While Saraç et al. (14) found no difference in platelet
function in postmenopausal women with HRT (transdermal
estradiol, estradiol 17-valerate/cyproterone acetate, or
tibolone) after 6 months, Yoshimura et al. (15) discovered
significant reduction in the activity of platelet-activating
factor acetylhydrolase (PAF-AH) within 2 weeks of a 10week conjugated equine estrogen treatment.
Despite its importance, there are limited reports about
the effect of hormone replacement therapy on MPV levels.

Other platelet aggregation methods have been evaluated
more frequently. However, there are many differences in
hormonal preparations with regard to type and dose of
estrogen and type of progestin combination. An important
point to consider is that the measurement of MPV is a
cost-effective and simple procedure compared to other
procedures. The MPV value can improve the follow-up
and management of postmenopausal women taking HRT.
It may aid the detection of CVD and may decrease future
complications of HRT use. Early detection of possible
CVD complications will increase the quality of life of
the patient and their chance of survival. To achieve these
results, a longer-term follow-up of the subjects and larger
series are necessary. One limitation of our study is the
moderate sample size and the 6-month follow-up period.
Additionally, the women in our study were healthy and
were not at risk of the conditions associated with HRT
use. After 6 months, we did not observe any change in
CVD risk markers such as MPV, lipid profile, and CRP
levels. These results suggest that younger postmenopausal
women taking HRT and women who initiated hormone
therapy close to menopause are not at increased risk
of CVD. Our findings are consistent with the study of
Rossouw et al. (3), which is a secondary analysis of the
Women’s Health Initiative’s randomized controlled trials
of hormone therapy.
In conclusion, menopause is an important phase in a
woman’s life, and postmenopausal women have a high risk
and incidence of CVD. It is suggested that initiation of HRT
close to menopause and at a younger age is associated with
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a lower incidence of CVD. MPV is a new and independent
risk factor for CVD, and the measurement of MPV is a
cost-effective and simple procedure that can be used in
the preassessment phase at the start of the treatment. High

MPV levels can be cautionary, even if the patient does not
carry any risk factors for CVD. Further studies with larger
series and a longer-term follow-up of cases are needed to
confirm these results.
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